Production (Stage)
Aligos Therapeutics, Inc.
ALGS
$5.50
-$0.17-3.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 137.86M | 56.94M | 74.92M | 94.54M | 112.74M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | -- | -- | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 5.34M | 5.20M | 4.90M | 5.03M | 5.33M |
| Total Current Assets | 143.21M | 62.14M | 79.82M | 99.57M | 118.06M |
|
|
|||||
| Total Current Assets | 143.21M | 62.14M | 79.82M | 99.57M | 118.06M |
| Net Property, Plant & Equipment | 6.86M | 7.33M | 7.97M | 8.61M | 9.21M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 632.00K | 627.00K | 635.00K | 631.00K | 625.00K |
| Total Assets | 150.70M | 70.09M | 88.43M | 108.81M | 127.90M |
|
|
|||||
| Total Accounts Payable | 4.46M | 2.57M | 2.74M | 6.82M | 2.84M |
| Total Accrued Expenses | 11.00M | 15.56M | 14.16M | 12.06M | 12.04M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 3.49M | 3.46M | 3.40M | 3.36M | 3.27M |
| Total Finance Division Other Current Liabilities | -- | 151.00K | 655.00K | 1.33M | 721.00K |
| Total Other Current Liabilities | -- | 151.00K | 655.00K | 1.33M | 721.00K |
| Total Current Liabilities | 18.95M | 21.74M | 20.96M | 23.56M | 18.88M |
|
|
|||||
| Total Current Liabilities | 18.95M | 21.74M | 20.96M | 23.56M | 18.88M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 4.39M | 4.92M | 5.73M | 6.48M | 7.21M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 10.92M | 72.41M | 11.64M | 11.54M | 42.02M |
| Total Liabilities | 34.25M | 99.07M | 38.33M | 41.58M | 68.11M |
|
|
|||||
| Common Stock & APIC | 690.92M | 588.58M | 585.38M | 583.33M | 580.98M |
| Retained Earnings | -574.92M | -618.01M | -535.86M | -516.60M | -521.66M |
| Treasury Stock & Other | 447.00K | 451.00K | 577.00K | 494.00K | 476.00K |
| Total Common Equity | 116.45M | -28.97M | 50.10M | 67.23M | 59.80M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 116.45M | -28.97M | 50.10M | 67.23M | 59.80M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 116.45M | -28.97M | 50.10M | 67.23M | 59.80M |
|
|
|||||